Novartis raised its forecast for 2010

Novartis AG Thursday unveiled figures in line with expectations in the second quarter of 2010 but has attracted attention in revising upward its forecasts for the current year.

The laboratory in Basel now expects growth at constant exchange rates, its revenues would fall between the middle and upper range of a single-digit rate (excluding Alcon).

In addition, operating margin and operating margin should increase core group "in the wake of the continued expansion and sustained improvement in productivity," said Thursday pharmaceutical company in a statement.

Novartis states that these projections do not account for the acquisition of a 77% stake in Alcon, adding hope to close the deal by the end of the year.

The CEO Joe Jimenez said during a teleconference that the price for the minority shareholders would not overcome and that Novartis was always 100% of Alcon.

These forecasts a little more spice to the presentation of second quarter figures, generally above expectations.

The net sales grew 11% to 11.7 billion dollars (9.2 billion euros), while analysts polled by Reuters had expected $ 11.5 billion.In the Pharmaceuticals Division, sales have improved to 7.7 billion, while markets were expecting 7.6 billion.

Net income rose 19% to 2.44 billion, slightly better than the 2.43 billion expected by the markets. Operating income increased by one quarter to 2.96 billion, exceeding forecasts of 2.8 billion.

Earnings per share has grown to $ 1.06 for a consensus which saw 1.05.

For the six months, Novartis recorded a turnover of 23.85 billion, up 18%. Net income rose 34% to 5.38 billion and operating 37% to 6.47 billion.

Comments are closed.

« The quarterly sales above expectations by Burberry Daimler will raise its forecasts after a strong second quarter »